{"name":"ApoPharma","slug":"apopharma","ticker":"","exchange":"","domain":"apodiscounter.de","description":"","hq":"Duiven","founded":0,"employees":"","ceo":"Oliver Scheel","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"deferiprone matching placebo tablets","genericName":"deferiprone matching placebo tablets","slug":"deferiprone-matching-placebo-tablets","indication":"Transfusion-dependent iron overload in patients with chronic anemias (e.g., thalassemia major, sickle cell disease)","status":"marketed"},{"name":"Desferal (deferoxamine)","genericName":"Desferal (deferoxamine)","slug":"desferal-deferoxamine","indication":"Chronic iron overload due to repeated blood transfusions (transfusional hemosiderosis)","status":"marketed"},{"name":"Ferriprox (deferiprone)","genericName":"Ferriprox (deferiprone)","slug":"ferriprox-deferiprone","indication":"Transfusional iron overload in patients with chronic anemia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Apo805K1","genericName":"Apo805K1","slug":"apo805k1","indication":"Other","status":"phase_2"},{"name":"Deferiprone oral solution","genericName":"Deferiprone oral solution","slug":"deferiprone-oral-solution","indication":"Other","status":"marketed"},{"name":"Ferriprox®","genericName":"Ferriprox®","slug":"ferriprox","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"deferiprone matching placebo tablets","genericName":"deferiprone matching placebo tablets","slug":"deferiprone-matching-placebo-tablets","phase":"marketed","mechanism":"Deferiprone is an iron chelator that binds and removes excess iron from the body, reducing iron-induced tissue damage.","indications":["Transfusion-dependent iron overload in patients with chronic anemias (e.g., thalassemia major, sickle cell disease)","Iron overload in patients with myelodysplastic syndromes"],"catalyst":""},{"name":"Apo805K1","genericName":"Apo805K1","slug":"apo805k1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Deferiprone oral solution","genericName":"Deferiprone oral solution","slug":"deferiprone-oral-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Desferal (deferoxamine)","genericName":"Desferal (deferoxamine)","slug":"desferal-deferoxamine","phase":"marketed","mechanism":"Deferoxamine is an iron chelator that binds free iron in the body and facilitates its excretion through urine and feces.","indications":["Chronic iron overload due to repeated blood transfusions (transfusional hemosiderosis)","Iron overload in patients with thalassemia major","Acute iron poisoning"],"catalyst":""},{"name":"Ferriprox (deferiprone)","genericName":"Ferriprox (deferiprone)","slug":"ferriprox-deferiprone","phase":"marketed","mechanism":"Deferiprone is an iron chelator that binds excess iron in the body and facilitates its excretion through urine.","indications":["Transfusional iron overload in patients with chronic anemia","Iron overload in thalassemia major"],"catalyst":""},{"name":"Ferriprox®","genericName":"Ferriprox®","slug":"ferriprox","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQd1BSdGNva0tpWmhrQ0lfb0F3M3JGX093cTRZczBURnhXVmkwU1VFenJVcndjM1o5X1dVc3YtekpmczhDdHVTSUJ1V3BGdUpvNHdyZElfZjh3V291MEhiYWFqNHp6NDRJZE12ZmRIR1EtajFndjJEUjVXYjJQNENUcnlvZ3FQR21mRHI5Uk9hNFc4U0RZc0Z1bmNB?oc=5","date":"2026-04-07","type":"regulatory","source":"openPR.com","summary":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight - openPR.com","headline":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNX28yVEw4SUg1amtLQ01TQ29WWEkzR3lUN2hrNWtvZUM0OXNVbTFoMzktWjgtVXhpaGVKVENBMnhFVzdDT2Y5Rk50SE9SSm92aXhXQ2xaUlBCbXRiMTFEV0czMFdjUzhzUUJ4blBYMzBweTF1OXo2akR1b25YNkZSbGlkZnVNU3c4cENoUFlTR0hVLUlMRzNsOENMS2JFdDk3SEFyRDR3c2ZuOHA4c2ZzMkExYlBGVkV5d2lzU1Zvc0hieDNfd0VLQm1ZNjJud0lFeGc?oc=5","date":"2024-04-22","type":"pipeline","source":"massbio.org","summary":"Delivering Innovative Therapies and Solutions: A Pharma Day® Q&A with Chiesi Global Rare Diseases - massbio.org","headline":"Delivering Innovative Therapies and Solutions: A Pharma Day® Q&A with Chiesi Global Rare Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE15Y2FPRDZxb0pFNFVKMGM0bUt5Zk5PT0JPUFc2RFY3dmRoYXYxclN0NzVLaTV0cFA3dGcxVzl0VlpodUh6ckh6MERUU0lPMDZVdzl5OWlzMEZkNmozazR2YTB3?oc=5","date":"2018-05-18","type":"regulatory","source":"InvestorPlace","summary":"FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs - InvestorPlace","headline":"FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"marketed":5,"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}